Embargo expired: 9/6/2012 5:00 PM EDT
Source Newsroom: American Society of Nephrology (ASN)
Assay could identify patients at increased risk for heart disease
• For the first time, a new test can measure the propensity for calcification to occur in an individual’s blood.
• The test could identify people at risk for vascular calcification, a major cause of heart disease.
Heart disease is the number one cause of death in kidney disease patients and the general population.
Newswise — Washington, DC (September 6, 2012) — A new test could help identify and treat individuals at risk of developing potentially deadly calcium deposits in their tissues and blood vessels, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). Heart disease is the number one killer of patients with chronic kidney disease (CKD), and vascular calcification is thought to play a major role.
Patients with CKD often have abnormally high blood calcium levels due to their compromised kidney function and the effects of commonly used medications. An accumulation of excess calcium can cause potentially deadly calcifications in tissues and blood vessels; however, physicians currently have no tools to determine an individual’s calcification risk.
Now Andreas Pasch, MD (University Hospital and University of Bern, Inselspital, in Switzerland) and his colleagues have developed the first test capable of measuring the propensity for calcification to occur in blood. Using their new assay, the investigators found that both the blood of mice deficient in a protein that inhibits calcification and the blood of CKD patients on dialysis had a reduced ability to inhibit calcification. Blood from healthy volunteers did not.
“Our test may identify patients at risk for the development of calcification, may become an important tool for identifying and testing calcification inhibitors, and may provide the basis for treatment monitoring in patients who receive such inhibitors,” said Dr. Pasch.
Study co-authors include Stefan Farese, MD, Steffen Gräber, Johanna Wald, Walter Richtering, PhD, Jürgen Floege, MD, and Willi Jahnen-Dechent, PhD.
Disclosures: The authors reported no financial disclosures.
The article, entitled “Nanoparticle-based Test Measures Overall Propensity for Calcification in Serum,” will appear online at http://jasn.asnjournals.org/ on September 6, 2012, doi: 10.1681/ASN.2012030240.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Founded in 1966, and with more than 13,500 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.
# # #